设为首页 加入收藏

TOP

Genexol PM Inj 30mg(Paclitaxel/L01CD01,注射用胶束化紫杉醇)
药店国别  
产地国家 韩国 
处 方 药: 是 
所属类别 30毫克/瓶 
包装规格 30毫克/瓶 
计价单位: 瓶 
生产厂家中文参考译名:
Samyang Biopharm
生产厂家英文名:
Samyang Biopharm
该药品相关信息网址1:
https://www.drugs.com/international/nanoxel.html
该药品相关信息网址2:
该药品相关信息网址3:
原产地英文商品名:
Genexol-PM 30mg/vial
原产地英文药品名:
Paclitaxel
中文参考商品译名:
Genexol-PM 30毫克/瓶
中文参考药品译名:
胶束化紫杉醇
曾用名:
简介:

 

部份中文紫杉醇胶束处方资料(仅供参考)
药品名称:注射用紫杉醇胶束
商品名称:Genexol PM
成分:紫杉醇100mg
剂型:注射剂
制造商:Samyang Biopharm 
推荐剂量:
每3周静脉给药300mg/m2,3小时以上;按以下剂量静脉给药3小时以上,随后静脉给药60mg/m2顺铂;每3周静脉给药260mg/m2,3小时以上。
包装:30毫克/瓶,100毫克/瓶。
该药品相关情况
注射用紫杉醇胶束为普通紫杉醇注射液的改良剂型产品,临床拟用于晚期乳腺癌、非小细胞肺癌、胃癌等的治疗。
Genexol® PM Inj.
Samyang biopharmaceuticals provides wide range of injections which includes genexol® pm inj. It is a patented new formulation of paclitaxel. The new formulation is free from toxic surfactant and allows significantly higher dosing of paclitaxel to the patients. Indication: it's a first line treatm...
Samyang biopharmaceuticals provides wide range of injections which includes genexol® pm inj. It is a patented new formulation of paclitaxel. The new formulation is free from toxic surfactant and allows significantly higher dosing of paclitaxel to the patients.
Indication:
it's a first line treatment for breast cancer, lung cancer, ovarian cancer.
Dosage: is administered at a dose of 300mg/m2 intravenously over 3 hours every 3weeks; it is administered over 3hours intravenously according to the dose below, followed by cisplatin at a dose of 60mg/m2 intravenously; it is administered at a dose of 260mg/m2 intravenously over 3hours every 3weeks. Packaging: 30mg /vial , 100mg /vial.
---------------------------------------------
Breast Cancer, Lung cancer, Pancreatic caner(cytotoxic chemotheraphy)
Genexol-PM is a polymeric micelle formulated paclitaxel, free of Cremophor EL. Objectives with Genexol-PM are to reduce Cremophor EL-related toxicities and to increase therapeutic efficacy. Polymeric micelles are composed of hundreds of amphiphilic diblock copolymers. Block copolymers include poly-(ethylene glycol) used as nonimmunogenic carriers and biodegradable core-forming poly-(D,L-lactic acid) to solubilize hydrophobic drug. Genexol-PM showed 3-times higher maximum tolerated dose in mice vs. Taxol.
Genexol-PM (vs. Taxol) showed 2-3-fold higher levels of paclitaxel in tissues including liver, spleen, kidney, lung, and tumors. In vivo antitumor efficacy of Genexol-PM was significantly higher than Taxol. Based on results from Phase I and II trials in Korea/US, the therapeutic dose recommended is 300mg/m2, much higher than Taxol (175 mg/m2). With favorable results from Phase II studies - Breast/Lung Cancer, Genexol-PM obtained a pre-market approval in Korea in July 2006. A phase IIa pancreatic cancer trial is on-going in US. 

】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇Genexol PM Inj 100mg(Paclitaxel.. 下一篇AVASTIN IV 400mg/16ml(Bevacizu..

相关栏目

最新文章

图片主题

热门文章

推荐文章